Prolymphocytic leukaemia is a rare and aggressive form of blood cancer that primarily affects older adults, typically those in their 60s. Unlike more common types of leukaemia, this disease progresses rapidly, challenging both patients and medical teams. Treatment approaches are evolving, with standard therapies and promising clinical research offering hope for better disease control and improved quality of life.

Understanding Treatment Goals and Approaches

When someone is diagnosed with prolymphocytic leukaemia, the primary goals of treatment focus on controlling disease progression, managing symptoms, and improving quality of life. Because this condition tends to advance quickly, medical decisions often need to be made promptly. The choice of treatment depends heavily on several factors, including whether the disease is the B-cell or T-cell type, the stage at which it is detected, the patient’s overall health status, and whether they have received previous treatment.^[1]

Treatment strategies must be highly individualized. Some patients may initially have what doctors call “inactive disease,” meaning they experience few or no symptoms at diagnosis. These individuals might not require immediate treatment but will be monitored closely, as the disease typically becomes active within one to two years. For most patients, however, treatment begins soon after diagnosis because of the aggressive nature of the condition.^[3]

Medical societies and expert panels have developed treatment guidelines based on the best available evidence. These recommendations help doctors decide which therapies are most appropriate. At the same time, researchers continue to investigate new therapeutic approaches through clinical trials. These studies test innovative drugs and treatment combinations that may one day become standard care. Patients and their families should understand that while standard treatments exist, the field is actively evolving with new discoveries emerging regularly.^[2]

Standard Treatment Approaches

The treatment landscape for prolymphocytic leukaemia has evolved significantly over the years. For T-cell prolymphocytic leukaemia (T-PLL), which accounts for about 20% of cases, certain therapies have become established as first-line options. Alemtuzumab, an anti-CD52 monoclonal antibody (a protein engineered to target specific markers on cancer cells), remains the most commonly used treatment for T-PLL. This medication works by recognizing a protein called CD52 that appears on the surface of prolymphocytes and healthy lymphocytes, binding to these cells and marking them for destruction by the immune system.^[4]

Alemtuzumab has shown the ability to produce responses in many patients with T-PLL. When it works, patients may experience reduction in their white blood cell counts, shrinkage of enlarged organs like the spleen or liver, and improvement in symptoms. However, the medication requires careful monitoring because it affects the immune system broadly, not just cancer cells. This means patients receiving alemtuzumab become more susceptible to infections while on treatment.^[7]

For B-cell prolymphocytic leukaemia (B-PLL), which represents about 80% of prolymphocytic leukaemia cases, treatment approaches differ somewhat. Some medical teams use therapies similar to those employed for chronic lymphocytic leukaemia (CLL), a related but slower-growing blood cancer. These may include combinations of chemotherapy drugs and antibody therapies. One regimen that has shown promise consists of bendamustine, a chemotherapy drug, combined with rituximab, an antibody that targets a protein called CD20 found on B cells.^[10]

In cases documented by medical researchers, patients with B-PLL who received bendamustine and rituximab achieved what doctors call “complete response,” meaning no detectable cancer remained after treatment. These responses lasted for more than two years in some individuals. The treatment typically involves multiple cycles given over several months, with each cycle consisting of intravenous infusions administered in a hospital or clinic setting. After the initial chemotherapy-antibody combination, some patients receive additional antibody treatment alone to help maintain their response.^[10]

Earlier treatment attempts for prolymphocytic leukaemia included older chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and purine analog drugs like fludarabine, cladribine, and pentostatin. Unfortunately, these approaches generally proved ineffective for prolymphocytic leukaemia, showing poor response rates and short-lived benefits. As a result, they are no longer considered optimal first-line treatments, though they may occasionally be used in specific circumstances.^[2][7]

Side effects from standard treatments can vary considerably. Alemtuzumab commonly causes reactions during or shortly after infusion, including fever, chills, and low blood pressure. More concerning is its effect on the immune system, which can lead to serious infections including viral, bacterial, and fungal diseases. Patients require preventive medications against certain infections and close monitoring of blood counts. The bendamustine and rituximab combination tends to cause lower blood cell counts, which may result in fatigue, increased infection risk, and bleeding tendencies. Nausea, hair thinning, and general weakness are also possible.^[10]

The duration of treatment varies based on the specific regimen and individual response. Some patients complete their initial treatment course within a few months, while others may continue therapy longer if they tolerate it well and continue benefiting. After completing treatment, regular follow-up visits are essential to monitor for disease recurrence and manage any long-term effects of therapy.^[3]

Treatment in Clinical Trials

Because standard treatments for prolymphocytic leukaemia often provide only temporary control, researchers worldwide are investigating new therapeutic approaches through clinical trials. These studies represent the pathway through which experimental treatments become proven therapies. Understanding what phase a clinical trial is in helps patients and families grasp what the study aims to accomplish.

Phase I trials primarily focus on safety, determining what dose of a new drug can be given without causing unacceptable side effects. Phase II trials examine whether the treatment actually works against the disease and continues to monitor safety in a larger group of patients. Phase III trials compare the new treatment to existing standard therapy to see if it offers advantages in effectiveness or tolerability.^[7]

One area of intense research interest involves targeting specific molecular pathways that cancer cells use for growth and survival. Scientists have discovered that cells in prolymphocytic leukaemia often have mutations (errors) in genes that normally regulate cell division and death. For instance, the JAK-STAT pathway is a cellular signaling system that controls cell growth. Abnormalities in genes called IL2RG, JAK1, JAK3, and STAT5B have been found in T-PLL cells. These mutations cause the pathway to remain constantly active, driving uncontrolled cell proliferation.^[2][7]

Researchers are testing drugs called JAK inhibitors that block this overactive signaling. These medications, which are already approved for other conditions, work by interfering with the JAK proteins, effectively putting the brakes on the growth signals that cancer cells depend on. Early laboratory studies and small patient trials have shown that JAK inhibitors can slow the growth of prolymphocytic leukaemia cells.^[7]

Another promising target is a protein called BCL2, which normally helps cells survive but becomes overactive in many cancers, including prolymphocytic leukaemia. When BCL2 is too active, cancer cells that should die naturally continue living and multiplying. BCL2 inhibitors are drugs designed to block this survival protein, allowing cancer cells to undergo programmed cell death. These medications have shown effectiveness in related blood cancers and are now being studied specifically for prolymphocytic leukaemia.^[7]

HDAC inhibitors represent another class of experimental drugs being explored. HDAC stands for histone deacetylase, a type of enzyme that affects how genes are turned on or off inside cells. When HDAC is blocked, certain genes that tell cancer cells to stop dividing may become active again. HDAC inhibitors have been tested in various blood cancers and are now being evaluated for prolymphocytic leukaemia in combination with other treatments.^[7]

Genes called TCL1 and MTCP1 are frequently abnormal in T-PLL. These genes act as oncogenes, meaning they promote cancer development when they malfunction. Research teams are working to develop therapies that specifically target the proteins these genes produce. While such treatments are still in early development, they represent an approach to addressing the root causes of the disease at the molecular level.^[7]

Some clinical trials are examining combinations of these targeted drugs with each other or with existing therapies like alemtuzumab. The idea behind combination approaches is that attacking the cancer through multiple mechanisms simultaneously may produce deeper and more durable responses than single-agent treatment. Preliminary results from some of these studies suggest that certain combinations may indeed improve outcomes, though more research is needed.^[7]

For patients whose disease responds well to initial treatment but who remain at high risk of relapse, stem cell transplantation is sometimes considered. This intensive procedure involves giving high doses of chemotherapy to eliminate cancer cells, followed by infusion of healthy blood-forming stem cells to rebuild the bone marrow. These stem cells typically come from a matched donor. Stem cell transplantation carries significant risks, including serious infections and complications from the body rejecting the donor cells or vice versa. Because of these risks, transplantation is generally reserved for younger, healthier patients who have achieved a good response to initial therapy and who have an appropriate donor available.^[2]

Clinical trials for prolymphocytic leukaemia are being conducted in various locations worldwide, including Europe, the United States, and other regions. Patient eligibility varies by study but typically depends on factors such as the specific type of prolymphocytic leukaemia, whether the disease is newly diagnosed or has returned after previous treatment, the patient’s age and overall health status, and function of major organs like the heart, kidneys, and liver.^[7]

Early results from some targeted therapy trials have been encouraging. Patients receiving these experimental treatments have shown improvements in blood counts, reductions in organ enlargement, and decreased symptoms. Safety profiles vary by drug, with some targeted therapies producing fewer severe side effects than traditional chemotherapy. However, it is important to remember that these are preliminary findings, and longer follow-up is needed to determine whether these improvements translate into longer survival or better long-term quality of life.^[7]

Most Common Treatment Methods

• Antibody therapy
  • Alemtuzumab (anti-CD52 antibody) is the standard first-line treatment for T-cell prolymphocytic leukaemia, targeting a protein on lymphocyte surfaces.
  • Rituximab (anti-CD20 antibody) is used in combination regimens for B-cell prolymphocytic leukaemia, binding to B-cell surface markers.
• Chemotherapy combinations
  • Bendamustine combined with rituximab has shown effectiveness in B-cell prolymphocytic leukaemia, with some patients achieving complete responses lasting over two years.
  • Older chemotherapy regimens like CHOP and purine analogs (fludarabine, cladribine, pentostatin) have generally proven ineffective for prolymphocytic leukaemia.
• Targeted therapy (in clinical trials)
  • JAK inhibitors target overactive JAK-STAT signaling pathways caused by mutations in genes like JAK1, JAK3, and STAT5B.
  • BCL2 inhibitors block survival proteins that allow cancer cells to avoid natural cell death.
  • HDAC inhibitors affect gene regulation by blocking histone deacetylase enzymes, potentially reactivating genes that suppress cancer growth.
• Stem cell transplantation
  • Considered for younger, healthier patients who achieve good response to initial treatment and have a matched donor available.
  • Involves high-dose chemotherapy followed by infusion of healthy donor stem cells to rebuild bone marrow.
  • Reserved for select patients due to significant risks including infections and graft complications.
• Monitoring without immediate treatment
  • Approximately 20-30% of patients initially present with inactive disease and may not require immediate treatment.
  • Close monitoring is essential as inactive disease typically progresses to active disease within 1-2 years.